Soliris (eculizumab) has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis (gMG) in paediatric patients who are anti-acetylcholine receptor (AChR) antibody-positive and whose
Elevate your financial IQ with Big Box Alerts. Expert advice, stock insights, real-time updates – all delivered to your inbox.
Menu
Weekly Newsletter
Find us on socials
© 2023 big board alerts | All rights reserved
DON’T MISS THE OPPORTUNITY TO JOIN OUR MARKET SUMMARY REPORT FOR A LIMITED TIME
By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.
